← Back to Search

Procedure

Peripheral Stem Cell Transplantation for Multiple Myeloma

Phase 2
Waitlist Available
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Non-Hodgkin's lymphoma with T-cell immunophenotypes included
Performance status Karnofsky 60-100%
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well peripheral stem cell transplantation works in treating patients with B-cell cancers.

Who is the study for?
This trial is for adults with B-cell cancers like multiple myeloma or lymphoma. Participants need a certain white blood cell and platelet count, heart function (LVEF) of at least 40%, good lung capacity, and can't be pregnant or have infections needing broad antibiotics. They must not have had chemotherapy, biologic, or endocrine therapy within the last 2 weeks.Check my eligibility
What is being tested?
The study is testing if high doses of chemotherapy followed by peripheral stem cell transplantation can effectively treat patients with multiple myeloma or other B-cell cancers. This phase II trial aims to see how well this approach works in killing cancer cells.See study design
What are the potential side effects?
High-dose chemotherapy can cause side effects such as nausea, hair loss, fatigue, increased risk of infection due to low blood counts, mouth sores, and potential damage to organs like the heart and lungs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My lymphoma is a type of T-cell non-Hodgkin's.
Select...
I can care for myself but may not be able to do active work.
Select...
I do not have an infection or fever that needs strong antibiotics.
Select...
I have been diagnosed with a specific type of blood cancer.
Select...
I am 18 years old or older.
Select...
My heart's pumping ability is at least 40%.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
604 Previous Clinical Trials
1,162,246 Total Patients Enrolled
23 Trials studying Lymphoma
4,343 Patients Enrolled for Lymphoma
David H. Vesole, MD, PhDStudy ChairMedical College of Wisconsin

Media Library

Peripheral Stem Cell Transplantation (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT00003163 — Phase 2
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Peripheral Stem Cell Transplantation Highlights & Side Effects. Trial Name: NCT00003163 — Phase 2
Peripheral Stem Cell Transplantation (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003163 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has this intervention obtained federal authorization?

"While Phase 2 trials lack information regarding the efficacy of a treatment, there is evidence indicating safety; thus it has been assessed as receiving a score of 2."

Answered by AI

Are there any opportunities to enroll in this research study at present?

"From the information presented on clinicaltrials.gov, it is evident that this particular trial has stopped recruiting participants as of January 3rd 2014. Initiated in September 1997 and now inactive, 2413 trials remain open for enrolment across the globe."

Answered by AI
~0 spots leftby Mar 2025